Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic DNA adenines susceptible to residual TadA-derived off-target deamination are specific nucleotide positions within the genome where Adenine Base Editors (ABEs) cause unintended A-to-G transitions. ABEs utilize an evolved tRNA-specific adenosine deaminase (TadA) fused to a CRISPR-Cas protein to perform targeted base editing [1]. However, the TadA domain can exhibit stochastic, guide-independent activity on single-stranded DNA (ssDNA) exposed during processes like transcription or replication [2]. This results in the conversion of adenosine to inosine, which is subsequently read as guanosine by DNA polymerases, creating permanent mutations [3]. These off-target events are a major concern in gene therapy because they can occur at high frequencies across the genome, potentially leading to the disruption of tumor suppressor genes or the activation of oncogenes [4]. Efforts to mitigate this include the engineering of high-fidelity TadA variants with reduced ssDNA affinity and the use of sensitive detection assays like Digenome-seq or GOTI to monitor genomic integrity [5].
Deamination of adenosine to inosine by TadA-derived enzymes, resulting in A-to-G transitions during DNA replication or repair.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic DNA adenines susceptible to residual TadA-derived off-target deamination.